LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?

Eur J Cancer. 2007 Mar;43(4):676-82. doi: 10.1016/j.ejca.2006.10.021. Epub 2007 Jan 18.

Abstract

The leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins are newly discovered negative regulators of growth factor signalling and proposed tumour suppressors. They antagonise signalling by interacting with growth factor receptors and by enhancing their ubiquitylation and degradation. Data on the expression of LRIG in human cancer have recently begun to accumulate; however, not all data appear consistent with the notion that the LRIG proteins always function as tumour suppressors. In the present review, we argue that the LRIG proteins could be double-edged swords, promoting or suppressing human cancer depending on cellular context.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Communication
  • Cell Proliferation
  • Forecasting
  • Homeostasis
  • Humans
  • Membrane Glycoproteins / antagonists & inhibitors*
  • Membrane Glycoproteins / physiology
  • Neoplasms / etiology
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Protein-Tyrosine Kinases / metabolism
  • Receptor, ErbB-2 / metabolism
  • Stem Cells / physiology

Substances

  • LRIG1 protein, human
  • Membrane Glycoproteins
  • Protein-Tyrosine Kinases
  • Receptor, ErbB-2